Clearside Biomedical Shares Key CLS-AX Trial Insights at Angiogenesis 2025

Clearside Biomedical recently presented critical findings from its ODYSSEY Phase 2b clinical trial at the Angiogenesis 2025 conference. The study evaluated CLS-AX, a targeted therapy for wet age-related macular degeneration (wet AMD), using Clearside’s innovative suprachoroidal injection technology. Dr. Roger Goldberg highlighted two key subgroup analyses that informed the design of the upcoming Phase 3 trial. The first analysis suggested that treatment-naïve patients showed promising stability in vision and retinal thickness, with 67% avoiding rescue treatment for six months. The second analysis recommended excluding participants with non-disease-related vision fluctuations, ensuring more reliable clinical outcomes.

Dr. Victor Chong, Clearside’s Chief Medical Officer, emphasized CLS-AX’s potential to provide long-lasting benefits while maintaining visual acuity. The findings indicate that refining patient selection could lead to more precise, real-world-applicable results in the Phase 3 trials. With CLS-AX’s highly selective mechanism and innovative delivery method, Clearside aims to set a new standard for durable and effective wet AMD treatment.